MD
Pediatrix Medical Group, Inc. Health Care Services-Hospitals Russell 3000
$29.82Close
$2.5BMarket cap
$16.97 – $29.8252-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 87 · stronger than 87% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Accumulation up-day volume 1.6× down-day volume over 50 sessions
Cautions
- Earnings shrinking EPS −30% year on year
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 1.8%
price change
1mo
up 15.9%
price change
12-month return
up 71%
market up 11% ·
its own up 56%
F-score
—
— Not assessed
Altman Z″
2.05
Moderate risk
P/E
15.0×
price / earnings
PEG
—
P/E / EPS growth
P/B
2.9×
price / book
Earnings yield
up 7.7%
EBIT / enterprise value
Cheaper than
78%
of the market · cheap
Revenue growth
down 5%
year on year
EPS growth
down 30%
latest quarter · -36 pts
Sales growth
up 2%
latest quarter · -2 pts
ROE
up 20%
return on equity
Free cash margin
up 14%
$271.1M FCF
D/E
0.69
long-term debt / equity
Net debt / EBITDA
1.0×
Interest cover
—EBIT / interest
Trade setup
ATR%
3.0%
$0.90 a day · 2×ATR $28.01
RS
87 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.6×
vs 50-day average
Up/down volume
1.57
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Revenue shrinking Revenue fell 4.9% over the year, from $2.0B to $1.9B.
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+5% vs market2 sessions after results
Financials
- Net 9%
- Free cash 14%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.9B | $2.0B | $2.0B | $2.0B | $1.9B |
| Operating income | $98.1M | $202.9M | $172.7M | $7.3M | -$68.7M | $208.8M |
| Net income | -$796.5M | $131.0M | $66.3M | -$60.4M | -$99.1M | $165.4M |
| Net margin | -46% | 7% | 3% | -3% | -5% | 9% |
| Earnings per share | -$9.55 | $1.53 | $0.79 | -$0.73 | -$1.19 | $1.94 |
| Free cash flow | $204.6M | $76.7M | $166.9M | $137.3M | $206.6M | $271.1M |
| Free cash margin | 12% | 4% | 8% | 7% | 10% | 14% |
| Cash | $1.1B | $387.4M | $9.8M | $73.3M | $229.9M | $375.2M |
| Long-term debt | $1.7B | $989.7M | $637.2M | $622.2M | $611.2M | $600.3M |
| Shareholders' equity | $747.5M | $896.5M | $891.6M | $849.1M | $764.9M | $865.9M |
| Shares outstanding | 85.59m | 86.42m | 82.95m | 84.02m | 85.87m | 82.98m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Nov 3, 2025 | Quarterly ↗ | Sep 30, 2025 | 34d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 20, 2025 | Annual ↗ | Dec 31, 2024 | 51d |
| Nov 1, 2024 | Quarterly ↗ | Sep 30, 2024 | 32d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 20, 2024 | Annual ↗ | Dec 31, 2023 | 51d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Aug 4, 2026 | Results ↗ |
| Jul 24, 2026 | Director or officer change · Regulation FD ↗ |
| Jul 15, 2026 | Results · Regulation FD ↗ |
| May 7, 2026 | Director or officer change · Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Feb 19, 2026 | Results ↗ |
| Nov 3, 2025 | Results ↗ |
| Aug 18, 2025 | Regulation FD · Other events ↗ |
| Aug 5, 2025 | Results ↗ |
| Jul 1, 2025 | Director or officer change · Regulation FD ↗ |
| May 8, 2025 | Shareholder vote ↗ |